Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts have given Compass Therapeutics a consensus rating of "Moderate Buy" from 14 firms (12 buys, 1 strong buy, 1 sell) with an average 12‑month price target of $14.20.
• Shares opened at $5.17 and were trading down about 5.1%; the company has a market cap of roughly $931M, 50/200‑day moving averages of $5.74/$5.15, reported Q EPS of ($0.09) beating estimates, and analysts forecast roughly (‑0.36) EPS for the fiscal year.
• Institutions own about 68.43% of the stock, with notable stake increases from Adage and Invesco, and Compass is a clinical‑stage biotech whose lead programs include CTX‑471 and DSP107.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $14.20.

Several analysts have recently issued reports on the stock. Craig Hallum initiated coverage on shares of Compass Therapeutics in a research report on Friday, February 13th. They set a "buy" rating and a $15.00 target price on the stock. D. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, January 6th. William Blair reissued an "outperform" rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Canaccord Genuity Group set a $13.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, February 4th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a research report on Wednesday, January 21st.

Compass Therapeutics Trading Down 5.1%

Shares of NASDAQ CMPX opened at $5.17 on Friday. The firm's 50-day moving average price is $5.74 and its 200-day moving average price is $5.15. The stock has a market capitalization of $931.07 million, a price-to-earnings ratio of -12.02 and a beta of 1.49. Compass Therapeutics has a 12-month low of $1.60 and a 12-month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. On average, equities analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Strs Ohio purchased a new stake in Compass Therapeutics in the 1st quarter worth about $34,000. Creative Planning purchased a new stake in Compass Therapeutics in the 2nd quarter worth about $30,000. XTX Topco Ltd purchased a new stake in Compass Therapeutics in the 2nd quarter worth about $84,000. Invesco Ltd. raised its position in Compass Therapeutics by 58.1% in the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company's stock worth $153,000 after purchasing an additional 21,578 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its position in Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company's stock worth $11,505,000 after purchasing an additional 449,868 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.